Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 1
2019 1
2021 1
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor.
Wakamatsu S, Jojima T, Hashiguchi M, Kishi H, Niitani T, Sakurai S, Iijima T, Kogai T, Tomaru T, Usui I, Aso Y. Wakamatsu S, et al. J Diabetes Complications. 2024 Jan;38(1):108650. doi: 10.1016/j.jdiacomp.2023.108650. Epub 2023 Nov 23. J Diabetes Complications. 2024. PMID: 38035640
Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol.
Jojima T, Sakurai S, Wakamatsu S, Iijima T, Saito M, Tomaru T, Kogai T, Usui I, Aso Y. Jojima T, et al. Among authors: wakamatsu s. Int J Cardiol. 2021 May 15;331:243-248. doi: 10.1016/j.ijcard.2021.01.063. Epub 2021 Feb 5. Int J Cardiol. 2021. PMID: 33556413 Clinical Trial.
The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T, Wakamatsu S, Kase M, Iijima T, Maejima Y, Shimomura K, Kogai T, Tomaru T, Usui I, Aso Y. Jojima T, et al. Among authors: wakamatsu s. Int J Mol Sci. 2019 Oct 22;20(20):5237. doi: 10.3390/ijms20205237. Int J Mol Sci. 2019. PMID: 31652578 Free PMC article.
The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.
Kato K, Suzuki K, Aoki C, Sagara M, Niitani T, Wakamatsu S, Yanagi K, Aso Y. Kato K, et al. Among authors: wakamatsu s. Expert Opin Pharmacother. 2017 Jun;18(8):743-751. doi: 10.1080/14656566.2017.1317748. Epub 2017 Apr 21. Expert Opin Pharmacother. 2017. PMID: 28426260 Clinical Trial.